152 related articles for article (PubMed ID: 23946646)
21. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.
Klawitter J; Zhang YL; Klawitter J; Anderson N; Serkova NJ; Christians U
Biomed Chromatogr; 2009 Dec; 23(12):1251-8. PubMed ID: 19517424
[TBL] [Abstract][Full Text] [Related]
22. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.
Singh N; Kumar L; Meena R; Velpandian T
Eur J Clin Pharmacol; 2009 Jun; 65(6):545-9. PubMed ID: 19214491
[TBL] [Abstract][Full Text] [Related]
23. Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry.
Zhang M; Moore GA; Fernyhough LJ; Barclay ML; Begg EJ
Anal Bioanal Chem; 2012 Oct; 404(6-7):2091-6. PubMed ID: 22865010
[TBL] [Abstract][Full Text] [Related]
24. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A; Widmer N; Guidi M; Montemurro M; Leyvraz S; Buclin T; Eap CB; Decosterd LA; Csajka C
Br J Clin Pharmacol; 2013 Apr; 75(4):1007-18. PubMed ID: 22891806
[TBL] [Abstract][Full Text] [Related]
25. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.
Bakhtiar R; Lohne J; Ramos L; Khemani L; Hayes M; Tse F
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Mar; 768(2):325-40. PubMed ID: 11888061
[TBL] [Abstract][Full Text] [Related]
26. Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection.
Tan KL; Ankathil R; Gan SH
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(30):3583-91. PubMed ID: 22000961
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
Chahbouni A; den Burger JC; Vos RM; Sinjewel A; Wilhelm AJ
Ther Drug Monit; 2009 Dec; 31(6):683-7. PubMed ID: 19865001
[TBL] [Abstract][Full Text] [Related]
28. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
[TBL] [Abstract][Full Text] [Related]
29. Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS.
Iqbal Z; Elliott M; Watson DG; Holyoake T; Jørgensen H
Pak J Pharm Sci; 2011 Jul; 24(3):285-91. PubMed ID: 21715261
[TBL] [Abstract][Full Text] [Related]
30. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
De Francia S; DʼAvolio A; Ariaudo A; Pirro E; Piccione F; Simiele M; Fava C; Calcagno A; Di Perri G; Saglio G
Ther Drug Monit; 2014 Jun; 36(3):410-2. PubMed ID: 24342895
[TBL] [Abstract][Full Text] [Related]
31. Imatinib plasma levels during successful long-term treatment of metastatic-gastrointestinal stromal tumors.
Sawaki A; Inaba K; Nomura S; Kanie H; Yamada T; Hayashi K; Okawaki M; Yamamura M; Yamaguchi Y; Hirai T; Orito E
Hepatogastroenterology; 2014 Oct; 61(135):1984-9. PubMed ID: 25713899
[TBL] [Abstract][Full Text] [Related]
32. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
Manley PW; Blasco F; Mestan J; Aichholz R
Bioorg Med Chem; 2013 Jun; 21(11):3231-9. PubMed ID: 23611771
[TBL] [Abstract][Full Text] [Related]
33. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.
Bakhtiar R; Khemani L; Hayes M; Bedman T; Tse F
J Pharm Biomed Anal; 2002 Jun; 28(6):1183-94. PubMed ID: 12049982
[TBL] [Abstract][Full Text] [Related]
34. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
[TBL] [Abstract][Full Text] [Related]
35. Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry.
Guetens G; Prenen H; De Boeck G; Highley M; de Wever I; van Oosterom AT; de Bruijn EA
J Sep Sci; 2006 Feb; 29(3):453-9. PubMed ID: 16544888
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.
Ohnishi K; Nakaseko C; Takeuchi J; Fujisawa S; Nagai T; Yamazaki H; Tauchi T; Imai K; Mori N; Yagasaki F; Maeda Y; Usui N; Miyazaki Y; Miyamura K; Kiyoi H; Ohtake S; Naoe T;
Cancer Sci; 2012 Jun; 103(6):1071-8. PubMed ID: 22364419
[TBL] [Abstract][Full Text] [Related]
37. Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
Buclin T; Widmer N; Biollaz J; Decosterd LA
Lancet Oncol; 2011 Jan; 12(1):9-11. PubMed ID: 21111679
[No Abstract] [Full Text] [Related]
38. Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients.
Ajimura TO; Borges KB; Ferreira AF; de Castro FA; de Gaitani CM
Electrophoresis; 2011 Jul; 32(14):1885-92. PubMed ID: 21710556
[TBL] [Abstract][Full Text] [Related]
39. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431
[TBL] [Abstract][Full Text] [Related]
40. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):177-82. PubMed ID: 22781602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
